Post by icemandios on Oct 26, 2017 16:40:08 GMT
From the 2016 Q4 CC, Moulder answering analyst question about Varubi oral which was launched 11/16/15:
"But we -- our December shipments put us in a number one market share position of the oral NK-1 receptor antagonist category. That category continued to shrink quite a bit up until the time we launched. So it's actually less than 10%. It's high single-digits. So the vast majority of the market opportunity is in IV. We focused on community oncology clinics that had in-office dispensing operations, and I think that's been an effective strategy. Now with IV, we'll be able to broaden our efforts with our expanded commercial organization to many more community clinics that did not have an office dispensing, about half; and the hospital segment, now that we have health systems managers in place. So the opportunity for VARUBI IV, of course is substantially greater; the IV market is about 90% of the market opportunity. So having the share penetration of one year that I just described and [technical difficulty] tells us that clinicians like the drug, the drugs delivering the benefit, and they're using as much as they can in that limited segment of the market, and that goes well for the same molecule, but in a formulation that clearly people preferred in many of the clinics because they can't dispense to enroll drug and hospitals. So that sets up us well for the IV launch."
"But we -- our December shipments put us in a number one market share position of the oral NK-1 receptor antagonist category. That category continued to shrink quite a bit up until the time we launched. So it's actually less than 10%. It's high single-digits. So the vast majority of the market opportunity is in IV. We focused on community oncology clinics that had in-office dispensing operations, and I think that's been an effective strategy. Now with IV, we'll be able to broaden our efforts with our expanded commercial organization to many more community clinics that did not have an office dispensing, about half; and the hospital segment, now that we have health systems managers in place. So the opportunity for VARUBI IV, of course is substantially greater; the IV market is about 90% of the market opportunity. So having the share penetration of one year that I just described and [technical difficulty] tells us that clinicians like the drug, the drugs delivering the benefit, and they're using as much as they can in that limited segment of the market, and that goes well for the same molecule, but in a formulation that clearly people preferred in many of the clinics because they can't dispense to enroll drug and hospitals. So that sets up us well for the IV launch."